^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Temodex (temozolomide gel)

    i
    Other names: SI 053
    Company:
    Belmedpreparaty, Double Bond Pharmaceutical
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    over1year
    TARGLIO: A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Double Bond Pharmaceutical AB | Trial completion date: Aug 2025 --> Dec 2025
    Trial completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Temodex (temozolomide gel)
    almost2years
    TARGLIO: A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Double Bond Pharmaceutical AB | Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Temodex (temozolomide gel)
    over2years
    TARGLIO: A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Double Bond Pharmaceutical AB | Trial completion date: May 2023 --> May 2024 | Initiation date: Sep 2021 --> Sep 2022 | Trial primary completion date: Mar 2023 --> Mar 2024
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Temodex (temozolomide gel)
    over3years
    TARGLIO: A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Double Bond Pharmaceutical AB
    Clinical • New P1 trial
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Temodex (temozolomide gel)